JP2015528802A5 - - Google Patents

Download PDF

Info

Publication number
JP2015528802A5
JP2015528802A5 JP2015522098A JP2015522098A JP2015528802A5 JP 2015528802 A5 JP2015528802 A5 JP 2015528802A5 JP 2015522098 A JP2015522098 A JP 2015522098A JP 2015522098 A JP2015522098 A JP 2015522098A JP 2015528802 A5 JP2015528802 A5 JP 2015528802A5
Authority
JP
Japan
Prior art keywords
her2 antibody
fucose
composition according
her2
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015522098A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015528802A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/065189 external-priority patent/WO2014013019A1/en
Publication of JP2015528802A publication Critical patent/JP2015528802A/ja
Publication of JP2015528802A5 publication Critical patent/JP2015528802A5/ja
Pending legal-status Critical Current

Links

JP2015522098A 2012-07-18 2013-07-18 フコシル化が低い抗her2抗体を用いた新規治療処置 Pending JP2015528802A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261673201P 2012-07-18 2012-07-18
US201261673216P 2012-07-18 2012-07-18
US201261673229P 2012-07-18 2012-07-18
US61/673,201 2012-07-18
US61/673,229 2012-07-18
US61/673,216 2012-07-18
EP12197768.0 2012-12-18
EP12197768 2012-12-18
PCT/EP2013/065189 WO2014013019A1 (en) 2012-07-18 2013-07-18 Novel therapeutic treatments with anti-her2 antibodies having a low fucosylation

Publications (2)

Publication Number Publication Date
JP2015528802A JP2015528802A (ja) 2015-10-01
JP2015528802A5 true JP2015528802A5 (enExample) 2016-09-08

Family

ID=49948317

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015522098A Pending JP2015528802A (ja) 2012-07-18 2013-07-18 フコシル化が低い抗her2抗体を用いた新規治療処置

Country Status (16)

Country Link
US (1) US20150166664A1 (enExample)
EP (1) EP2874658A1 (enExample)
JP (1) JP2015528802A (enExample)
KR (1) KR20150036710A (enExample)
CN (1) CN104394887A (enExample)
AU (1) AU2013291964B2 (enExample)
BR (1) BR112014032169A2 (enExample)
CA (1) CA2875486A1 (enExample)
EA (1) EA201590237A1 (enExample)
IL (1) IL236714A0 (enExample)
MA (1) MA37961A1 (enExample)
MX (1) MX2015000730A (enExample)
NZ (1) NZ701974A (enExample)
SG (1) SG11201407841YA (enExample)
WO (1) WO2014013019A1 (enExample)
ZA (1) ZA201408938B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU92659B1 (en) * 2015-02-23 2016-08-24 Glycotope Gmbh Glycooptimized antibody drug conjugates
CA3057758A1 (en) * 2017-03-29 2018-10-04 Glycotope Gmbh Pd-l1 and ta-muc1 antibodies
US12103978B2 (en) * 2018-06-15 2024-10-01 Shanghai Miracogen Inc. Methods and materials for treating cancer
KR102871791B1 (ko) 2018-09-10 2025-10-15 미라티 테라퓨틱스, 인크. 병용 요법
WO2020056338A1 (en) * 2018-09-14 2020-03-19 Prelude Corporation Method of selection for treatment of subjects at risk of invasive breast cancer
EP4190818A4 (en) * 2020-07-28 2024-08-07 Bio-Thera Solutions, Ltd. ANTI-HER2 ANTIBODY AND ITS USE

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
ATE440959T1 (de) 2000-06-28 2009-09-15 Glycofi Inc Verfahren für die herstellung modifizierter glykoproteine
KR100988949B1 (ko) 2001-10-25 2010-10-20 제넨테크, 인크. 당단백질 조성물
AU2003236017B2 (en) 2002-04-09 2009-03-26 Kyowa Kirin Co., Ltd. Drug containing antibody composition
CZ308720B6 (cs) * 2003-01-22 2021-03-24 Roche Glycart Ag Fúzní konstrukty a jejich použití pro přípravu protilátek se zvýšenou vazebnou afinitou k receptorům Fc a efektorovou funkcí
FR2858235B1 (fr) 2003-07-31 2006-02-17 Lab Francais Du Fractionnement Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
JPWO2005053742A1 (ja) * 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
US7273608B2 (en) * 2004-03-11 2007-09-25 City Of Hope Humanized anti-CEA T84.66 antibody and uses thereof
DOP2006000029A (es) * 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
PT2073842E (pt) * 2006-09-10 2015-04-07 Glycotope Gmbh Utilização de células humanas provenientes de uma leucemia mielóide para expressão de anticorpos
AU2010303415B2 (en) * 2009-10-07 2015-02-19 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
US20120258496A1 (en) * 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells

Similar Documents

Publication Publication Date Title
US20220306745A1 (en) Use of an activatable anti-pdl1 antibody and an anti-ctla-4 antibody in a combination therapy for the treatment of cancer
JP2016536361A5 (enExample)
JP7408396B2 (ja) 併用療法
JP2018518454A5 (enExample)
JP2020512281A5 (enExample)
JP7797875B2 (ja) 癌の治療及び/又は予防のための医薬品
JP2017537105A5 (enExample)
FI3805268T3 (fi) Vasta-aine joka sitoo ErbB-2:ta ja ErbB-3:a
JP2022531408A5 (enExample)
FI3799885T3 (fi) Lymfosyyttien estoreittien neutralointi
JP2021510736A5 (enExample)
JP2018509390A5 (enExample)
JP2016094424A5 (enExample)
JP2016516800A5 (enExample)
JP2018512402A5 (enExample)
JP2019513726A5 (enExample)
JP2013508292A5 (enExample)
JP2014525926A5 (enExample)
AU2012296907A1 (en) Combination therapy with an anti - CD19 antibody and a nitrogen mustard
WO2013024097A1 (en) Combination therapy with an anti - cd19 antibody and a nitrogen mustard
JP2025060639A (ja) Pd-1/pd-l1シグナル伝達阻害剤に不応答性のがんの処置方法および医薬
JP2018529661A5 (enExample)
JP2018533569A5 (enExample)
JP2023510429A5 (enExample)
JPWO2022270524A5 (enExample)